Phesgo and Tecentriq Performance and Approvals
Q1 2023: Diagnostics Division highlights
Good base business growth, partially offsetting COVID-19 sales decrease
Roche
CHFbn
Core Lab
Molecular Lab
-48%
Point of Care
-72%
Diabetes Care
-5%
YoY CER growth
•
+7%
Immunodiagnostics (+9%)
Clinical Chemistry (+9%)
•
Custom biotech (-9%)
•
Virology base business (+12%)
•
Blood Screening (+15%)
•
Cervical Cancer (+22%)
•
COVID-19 (-87%)
.
.
POC Rapid A/G (-87%)
POC Molecular (-27%)
POC base business (+13%)
Blood glucose monitoring (-4%)
Insulin delivery systems (-20%)
Advanced staining (+6%)
• Companion diagnostics (+11%)
EMEA
Pathology Lab
+7%
North America
•
.
Asia-Pacific
Latin America
0.0
0.5
1.0
1.5
2.0
CER-Constant Exchange Rates; POC=point of care; EMEA-Europe, Middle East and Africa;
36
56View entire presentation